About us
RTW is a life sciences investment and innovation firm
Made up of scientists, entrepreneurs and investors; we forge new paths together, invest in each other and believe in each other.
77
team members at RTW
Headquartered in New York with offices in London and Shanghai, RTW invests across the full lifecycle of companies including company creation, early stage venture capital, crossover, and public company investments.
Key facts
At the end of the day, we’re looking to identify companies that are going to make a major difference in patients’ lives and support them both financially and through our expertise. As a result, we hope to participate in the value creation that comes with their success.
70
private companies invested in*
*as of July 2022
Great science takes place everywhere
RTW prioritizes advancing early stage scientific development as reflected in its global portfolio.
We have a core focus on the US, with deep coverage of opportunities from academia to mid-size public companies. We apply a full range of deal execution and company building capabilities.
We are committed to fostering the UK life sciences ecosystem, partnering with universities, in-licensing academic programs, and supporting UK entrepreneurs with capital and expertise.
Portfolio companies include argenx, uniQure, ProQR, and iTeos Therapeutics.
Portfolio companies including Rocket Pharmaceuticals
Companies based here include UroGen Pharma, BrainsWay
Based in Shanghai, JiXing is a conduit to bring western innovation to the Chinese market through a trusted and established China-based company
Our approach
Identify unmet needs
We believe the best way to create value for investors is to find and support innovations that solve unmet needs for patients.
Invest in relationships
We believe in developing long-term relationships with great entrepreneurs and scientists who are as passionate about medicine as we are.
Support through the lifecycle
Our high-conviction approach means we are committed for the long term, allowing us to help drive value creation at each stage for investors, companies, and ultimately patients.
Our story
Doctors, academics, and drug developers. Seasoned venture capitalists and investment bankers. Experienced lawyers, data scientists, and company operators. We all work as one team. Applying our collective power to build successful companies around brilliant ideas.
Also in this section
Our vision, values and purpose
These things shape the what, why, and how of our firm. They're what drives our impact on our partners, companies, colleagues, patients, and the world around us.
Our strategy
Our strategy starts with science. Scientific research and idea generation are our foundation and the way we discover sources of transformational innovations. We build on that science with our financial investment, company building, transactional, and legal expertise to create impact.
Our business model
Science doesn't care about company stage, so neither do we. Full lifecycle investing means we can invest in and support the best science regardless of where it sits. From company creation to early stage venture to crossover and public company investing. Our structure and financial capabilities allow us the flexibilty to support our portfolio companies' needs through a broad range of financing models.
Discussing the power of partnership with Prometheus Biosciences
Post-launch, pre-cliff: The R&D congress ignores
